Equity Overview
Price & Market Data
Price: $0.965
Daily Change: +$0.0481 / 4.98%
Daily Range: $0.85 - $1.07
Market Cap: $7,297,627
Daily Volume: 53,961
Performance Metrics
1 Week: 9.90%
1 Month: -0.02%
3 Months: -18.72%
6 Months: -39.41%
1 Year: -65.64%
YTD: 1.92%
Company Details
Employees: 6
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts.